Program
enzalutamide
Also written as “Enzalutamide”, “MDV3100” and “HC-1119”.
Its studies are mostly in Prostatic Neoplasms · Neoplasms · Breast Neoplasms · Prostatic Neoplasms, Castration-Resistant · Neoplasm Metastasis, led by 6 companies.
Drug pageEnzalutamide: every studyMany companies study it; this page follows only the 54 they lead. All 176 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharmaits history only | 313 open or running | phase 4since Oct 31, 2013 | Jan 18, 2011 | Apr 30, 2027phase 1 · NCT07783282 |
| Pfizerits history only | 162 open or running | phase 4since Nov 18, 2013 | Jul 31, 2007 | none ahead |
| Hinova Pharmaceuticalsits history only | 41 open or running | phase 3since Feb 17, 2019 | Dec 11, 2018 | none ahead |
| Alessa Therapeuticsits history only | 11 open or running | phase 1since Dec 14, 2023 | Dec 14, 2023 | Dec 30, 2028phase 1 · NCT06257693 |
| Applied Biologyits history only | 10 open or running | phase 3since Jul 28, 2021 | Jul 28, 2021 | none ahead |
| Hinova Pharmaceuticals USAits history only | 10 open or running | phase 3since Feb 20, 2019 | Feb 20, 2019 | none ahead |
Also a collaborator on its studies: Exelixis, Novartis, Clovis Oncology, Johnson & Johnson, Medivation LLC, a wholly owned subsidiary of Pfizer and Gilead Sciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 38 studies since Jul 31, 2007.
- Feb 29, 2016Phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT02799745 · 227 enrolled · United States, Canada
- Sep 7, 2016Phase 3 study in Breast NeoplasmsPfizer · NCT02929576 · United States
- Sep 27, 2016Phase 4 study in Prostatic NeoplasmsAstellas Pharma · NCT02918968 · 206 enrolled · Japan
- Nov 7, 2016Phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT02960022 · 900 enrolled · United States, Argentina, Australia and more
- Aug 20, 2018Phase 4 study in Metastatic Castration Resistant Prostate CancerAstellas Pharma · NCT03641560 · 52 enrolled · India
- Dec 11, 2018Hinova Pharmaceuticals’ first studies: 3 phase 1 studies in Metastatic Castration Resistant Prostate CancerNew to Hinova PharmaceuticalsHinova Pharmaceuticals · NCT03778047, NCT03776968, NCT03774056
- Feb 17, 2019Phase 3 study in MCRPCHinova Pharmaceuticals · NCT03851640 · 417 planned · China
- Feb 20, 2019Hinova Pharmaceuticals USA’s first study: phase 3 study in Prostate Cancer MetastaticNew to Hinova Pharmaceuticals USAHinova Pharmaceuticals USA · NCT03850795 · 104 enrolled · United States, Australia, Austria and more
- Aug 19, 2019Phase 3 study in Metastatic Hormone Sensitive Prostate CancerAstellas Pharma · NCT04076059 · 180 enrolled · China
- Sep 17, 2019Phase 1 study in Prostatic NeoplasmsAstellas Pharma · NCT04094519 · 24 enrolled · Moldova, Republic of
- Mar 25, 2021Phase 3 study in Prostatic NeoplasmsPfizer · NCT04821622 · 599 enrolled · United States, Argentina, Australia and more
- Jul 28, 2021Applied Biology’s first study: phase 3 study in COVID-19 Respiratory InfectionNew to Applied BiologyApplied Biology · NCT04986176 · 602 enrolled
- Dec 14, 2023Alessa Therapeutics’ first study: phase 1 study in Prostate AdenocarcinomaNew to Alessa TherapeuticsAlessa Therapeutics · NCT06257693 · 45 planned · United States
- Aug 20, 2026Phase 1 study in Prostatic NeoplasmsAstellas Pharma · NCT07783282 · 56 planned · Bulgaria
Ahead
- Apr 30, 2027Primary completion: phase 1 study in Prostatic NeoplasmsAstellas Pharma · NCT07783282
- Dec 30, 2028Primary completion: phase 1 study in Prostate AdenocarcinomaAlessa Therapeutics · NCT06257693
- Jul 31, 2029Primary completion: phase 2 study in Prostatic NeoplasmsAstellas Pharma · NCT02960022
TargetBeta
“A deuterated form of enzalutamide, an orally bioavailable, organic, non-steroidal small molecule targeting the androgen receptor (AR) ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule
Other programs on AR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| apalutamiderule | Johnson & Johnson | phase 4 | 31 |
| darolutamiderule | Bayer | phase 4 | 26 |
| Clascoteronerule | cassiopea-spa | phase 4 | 19 |
| ostarinerule | gtx | phase 3 | 15 |
| rezvilutamiderule | Jiangsu HengRui Medicine | phase 3 | 13 |
| dezandrodegrule | Bristol-Myers Squibb | phase 3 | 5 |
| Cyproterone Acetaterule | Eurofarma Laboratorios | phase 3 | 4 |
| Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915 | Johnson & Johnson | phase 3 | 3 |
| HRS-5041 | Jiangsu HengRui Medicine | phase 2 | 6 |
| luxdegalutamide | Novartis | phase 2 | 3 |
| luxdegalutamide | Novartis | phase 2 | 2 |
| Androgen Receptor Degrader AZD9750rule | AstraZeneca | phase 2 | 1 |
Studies
All 54 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07783282Prostatic Neoplasms · Bulgaria | 1 | Recruiting | Astellas Pharma | Apr 30, 2027 | 56 |
| NCT06257693Prostate Adenocarcinoma · United States | 1 | Recruiting | Alessa Therapeutics | Dec 30, 2028 | 45 |
| NCT04986176COVID-19 Respiratory Infection | 3 | UNKNOWN | Applied Biology | Dec 31, 2022 | 602 |
| NCT04821622Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Pfizer | Feb 18, 2026 | 599 |
| NCT04094519Prostatic Neoplasms · Moldova, Republic of | 1 | Completed | Astellas Pharma | Dec 27, 2020 | 24 |
| NCT04076059Metastatic Hormone Sensitive Prostate Cancer · China | 3 | Active, not recruiting | Astellas Pharma | Nov 18, 2022 | 180 |
| NCT03850795Prostate Cancer Metastatic · United States, Australia, Austria and more | 3 | Terminated | Hinova Pharmaceuticals USA | Jun 28, 2024 | 104 |
| NCT03851640MCRPC · China | 3 | Recruiting | Hinova Pharmaceuticals | Sep 2025 | 417 |
| NCT03778047Metastatic Castration Resistant Prostate Cancer · China | 1 | Completed | Hinova Pharmaceuticals | Oct 24, 2018 | 10 |
| NCT03776968Metastatic Castration Resistant Prostate Cancer · China | 1 | Completed | Hinova Pharmaceuticals | Jan 15, 2018 | 47 |
| NCT03774056Metastatic Castration Resistant Prostate Cancer · China | 1 | Completed | Hinova Pharmaceuticals | Sep 26, 2018 | 43 |
| NCT03641560Metastatic Castration Resistant Prostate Cancer · India | 4 | Completed | Astellas Pharma | Feb 20, 2024 | 52 |
| NCT02960022Prostatic Neoplasms · United States, Argentina, Australia and more | 2 | Active, not recruiting | Astellas Pharma | Jul 31, 2029 | 900 |
| NCT02918968Prostatic Neoplasms · Japan | 4 | Completed | Astellas Pharma | Mar 27, 2020 | 206 |
| NCT02929576Breast Neoplasms · United States | 3 | Withdrawn | Pfizer | Apr 2019 | 0 |
| NCT02799745Prostatic Neoplasms · United States, Canada | 2 | Completed | Astellas Pharma | Aug 28, 2020 | 227 |
| NCT02677896Metastatic Hormone Sensitive Prostate Cancer · United States, Argentina, Australia and more | 3 | Completed | Astellas Pharma | Oct 14, 2018 | 1,150 |
| NCT02528643Advanced Hepatocellular Carcinoma · United States, Canada, Hong Kong and more | 2 | Completed | Astellas Pharma | Oct 2, 2017 | 165 |
| NCT02441517Neoplasm Metastasis · United States | 4 | Terminated | Astellas Pharma | Mar 15, 2017 | 4 |
| NCT02384382Prostatic Neoplasms · United States | 2 | Completed | Pfizer | May 3, 2019 | 23 |
| NCT02319837Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Active, not recruiting | Pfizer | Jan 31, 2023 | 1,068 |
| NCT02294461Bulbo-Spinal Atrophy, X-Linked · China, Hong Kong, South Korea and more | 3 | Completed | Astellas Pharma | Sep 20, 2015 | 395 |
| NCT02288247Neoplasm Metastasis · Austria, Belgium, Czechia and more | 3 | Completed | Astellas Pharma | Apr 30, 2020 | 688 |
| NCT02225093Prostatic Neoplasms · Moldova, Republic of | 1 | Completed | Astellas Pharma | Feb 3, 2014 | 12 |
| NCT02138799Drug-Drug Interaction (DDI) · Germany | 1 | Completed | Astellas Pharma | Sep 2013 | 28 |
| NCT02138162Severe Hepatic Impairment · Bulgaria | 1 | Completed | Astellas Pharma | Mar 2014 | 16 |
| NCT02124668Prostatic Neoplasms · Georgia, Russian Federation | 2 | Completed | Astellas Pharma | May 25, 2017 | 30 |
| NCT02116582Metastatic Castration-Resistant Prostate Cancer · Belgium, France, Germany and more | 4 | Completed | Astellas Pharma | May 8, 2016 | 215 |
| NCT02091960Breast Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Astellas Pharma | Feb 28, 2017 | 103 |
| NCT02007512Breast Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Pfizer | Sep 23, 2016 | 247 |
| NCT02003924Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Jun 28, 2017 | 1,401 |
| NCT01995513Prostatic Neoplasms · United States, Australia, Belgium and more | 4 | Completed | Pfizer | Nov 15, 2016 | 509 |
| NCT01977651Seizures · United States, Argentina, Australia and more | 4 | Completed | Astellas Pharma | Feb 1, 2016 | 424 |
| NCT01913379Healthy Subjects · France | 1 | Completed | Astellas Pharma | Dec 2011 | 41 |
| NCT01911741Healthy Subjects · Germany | 1 | Completed | Astellas Pharma | Mar 2013 | 55 |
| NCT01911728Pharmacokinetics of MDV3100 · South Africa | 1 | Completed | Astellas Pharma | Feb 21, 2012 | 14 |
| NCT01911715Healthy Subjects · Netherlands | 1 | Completed | Astellas Pharma | Jul 2011 | 6 |
| NCT01902251Prostatic Neoplasms · United States | 1 | Completed | Astellas Pharma | Oct 2013 | 27 |
| NCT01889238Breast Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Pfizer | Mar 1, 2015 | 118 |
| NCT01901133Kidney Diseases · Moldova, Republic of | 1 | Completed | Astellas Pharma | Jan 2012 | 33 |
| NCT01664923Prostatic Neoplasms · United States | 2 | Completed | Pfizer | Feb 2015 | 396 |
| NCT01663415Neoplasms | 2 | Withdrawn | Astellas Pharma | Oct 2014 | 0 |
| NCT01650194Neoplasms · United States | 2 | Completed | Astellas Pharma | Jan 4, 2018 | 60 |
| NCT01597193Breast Neoplasms · United States | 1 | Completed | Pfizer | Dec 15, 2015 | 101 |
| NCT01547299Prostatic Neoplasms · United States, Canada | 2 | Completed | Pfizer | Nov 30, 2013 | 52 |
| NCT01565928Prostatic Neoplasms · United States | 1 | Completed | Pfizer | Jul 1, 2013 | 23 |
| NCT01534052Prostatic Neoplasms · United States, Moldova, Republic of, South Africa | 2 | Completed | Astellas Pharma | Apr 18, 2017 | 52 |
| NCT01302041Prostatic Neoplasms · Belgium, Czechia, Denmark and more | 2 | Completed | Astellas Pharma | Jul 29, 2012 | 67 |
| NCT01288911Prostatic Neoplasms · United States, Belgium, Canada and more | 2 | Completed | Astellas Pharma | Oct 19, 2014 | 375 |
| NCT01284920Prostatic Neoplasms · Japan | 2 | Completed | Astellas Pharma | Jul 12, 2012 | 47 |
| NCT01212991Prostatic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Pfizer | Sep 30, 2013 | 1,717 |
| NCT01091103Metastatic Progressive Castration-resistant Prostate Cancer · United States | 2 | Completed | Pfizer | Feb 29, 2012 | 60 |
| NCT00974311Prostatic Neoplasms · United States, Argentina, Australia and more | 3 | Completed | Pfizer | Sep 15, 2011 | 1,199 |
| NCT00510718Prostatic Neoplasms · United States | 1 | Completed | Pfizer | Dec 8, 2008 | 140 |
How it is read
Names in the registry
- “Enzalutamide”, 40 entries
- “enzalutamide”, 13 entries
- “MDV3100”, 8 entries
- “HC-1119”, 4 entries
- “HC1119”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 41 studies
- Neoplasms, 6 studies
- Breast Neoplasms, 5 studies
- Prostatic Neoplasms, Castration-Resistant, 2 studies
- Neoplasm Metastasis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.